| 27.50 Delayed Data As of 4:00pm ET |  +0.50 / +1.85%Today’s Change | 16.56 Today|||52-Week Range 29.44 | +40.74% Year-to-Date |
| Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates Aug 08 / Zacks.com - Paid Partner Content | Horizon Therapeutics (HZNP) Surpasses Q2 Earnings and Revenue Estimates Aug 07 / Zacks.com - Paid Partner Content |
| Horizon Pharma PLC (HZNP) Q2 2019 Earnings Call Transcript Aug 07 / MotleyFool.com - Paid Partner Content |
| Previous close | 27.00 |
| Today’s open | 27.17 |
| Day’s range | 26.94 - 27.62 |
| Volume | 972,809 |
| Average volume (3 months) | 1,830,760 |
| Market cap | $5.0B |
| Earnings growth (last year) | +82.28% |
| Earnings growth (this year) | -0.55% |
| Earnings growth (next 5 years) | +17.60% |
| Revenue growth (last year) | +14.33% |
| P/E ratio | 70.5 |
| Price/Sales | 2.69 |
| Price/Book | 4.33 |
| Today’s change | Today’s % change | |
|---|---|---|
| RGENRepligen Corp | +0.96 | +1.04% |
| GWPHGW Pharmaceuticals P... | -0.02 | -0.01% |
| GRFSGrifols SA | +0.11 | +0.50% |
| ALLKAllakos Inc | +0.40 | +0.45% |
| Next reporting date | November 11, 2019 |
| EPS forecast (this quarter) | $0.49 |
| Annual revenue (last year) | $1.2B |
| Annual profit (last year) | -$74.2M |
| Net profit margin | -6.14% |
Sector Health Technology |
Industry Pharmaceuticals: Other |
Chairman, President & Chief Executive Officer Timothy P. Walbert |
Senior VP-Business Operations & Government Affairs Robert W. Metz |
Corporate headquarters Dublin, Dublin |
